Lexaria Bioscience Corp reports results for the quarter ended November 30 - Earnings Summary

• Lexaria Bioscience Corp LEXX.OQ reported a quarterly adjusted loss of 16 cents​​ per share for the quarter ended November 30, lower than the same quarter last year, when the company reported EPS of -13 cents. The lone analyst forecast for the quarter was for a loss of 12 cents per share.

• Revenue was $183.92 thousand​; analysts expected $100.00 thousand.

• Lexaria Bioscience Corp's reported EPS for the quarter was a loss of 16 cents​.

• Lexaria Bioscience Corp shares had risen by 5.2% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 33.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Lexaria Bioscience Corp is $10.00

This summary was machine generated from LSEG data January 10 at 10:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)